<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598270</url>
  </required_header>
  <id_info>
    <org_study_id>ENGOT-Ov41/GEICO 69-O/ANITA</org_study_id>
    <secondary_id>2018-000366-11</secondary_id>
    <secondary_id>ENGOT-Ov41</secondary_id>
    <secondary_id>GEICO 69-O</secondary_id>
    <nct_id>NCT03598270</nct_id>
  </id_info>
  <brief_title>Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)</brief_title>
  <acronym>ANITA</acronym>
  <official_title>A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) &gt;6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Israeli Society of Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MaNGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Cáncer de Ovario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atezolizumab in this study is expected to have a positive benefit-risk profile for the
      treatment of patients with platinum-sensitive relapse of ovarian cancer. Of interest,
      atezolizumab is being investigated also in combination with platinum-based doublet
      chemotherapy in second line (2L)/ third line (3L) platinum-sensitive recurrent ovarian cancer
      patients in ATALANTE (NCT02891824), which also includes bevacizumab in the combination. The
      study is proceeding as expected after &gt;100 patients enrolled and under independent Data
      Monitoring Committee (IDMC) supervision.

      Platinum-containing therapy is considered the treatment of choice for patients with
      platinum-sensitive relapse. However the duration of response and the prolongation of the
      progression free interval with chemotherapy are usually brief, among other because these
      chemotherapy regimens cannot be continued until progression as they are associated with
      neurological, renal and hematological toxicity and cannot generally be tolerated for more
      than about 6 to 9 cycles.

      Niraparib received FDA approval in March 2017 as maintenance treatment of adult patients with
      recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete
      or partial response to platinum-based chemotherapy. Recently, the European Medicines Agency
      (EMA) has also approved niraparib as maintenance monotherapy. Despite the progress brought
      about by niraparib, there is a need for a more effective treatment to extend the progression
      free interval in this patient population. The combination with immune checkpoint inhibitors
      such as anti-death protein 1 (anti-PD1) or anti-death protein ligand 1 (anti-PD-L1) has a
      compelling rationale to this aim, especially under the light of the emerging clinical data of
      this combination.

      The use of atezolizumab concurrent to platinum-containing chemotherapy followed by niraparib
      as maintenance therapy after completion of chemotherapy, as per normal clinical practice, may
      provide further benefit to patients in terms of prolonging the progression free interval and
      increasing the interval between lines of chemotherapy, hence delaying further hospitalization
      and the cumulative toxicities associated with chemotherapy. Additionally, preliminary studies
      with atezolizumab suggest an acceptable tolerability profile for long term clinical use in
      recurrent ovarian cancer patients and other indications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blinded, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Atezolizumab and placebo treatment will be double blinded, unknown to both the subject and the study staff, including the treating physician. In order to maintain the blind, atezolizumab and placebo will be identical in appearance and packaging.
The study medication will be labeled using a unique kit id number, which is linked to the randomization scheme. The active and placebo kits will be presented in the same packaging to ensure blinding of the study medication Individual treatment codes, indicating the treatment randomization for each randomized patient, will be available to the investigator(s) or pharmacists from the IVRS/IWRS. Routines for this will be described in the Interactive Voice Response System/Interactive Web Response System (IVRS/IWRS) user manual that will be provided to each centre.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>Period from study entry (day of randomization) until disease progression, death or date of last contact. Progression will be based on tumor assessment made by the investigators according to the RECIST v1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>60 months</time_frame>
    <description>The observed length of life from entry into the study (day of randomization) to death due to any cause, or the date of last contact if patient alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent therapy or death (TFST)</measure>
    <time_frame>60 months</time_frame>
    <description>Time from the date of randomization in the current study to the start date of the first subsequent anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second subsequent therapy or death (TSST)</measure>
    <time_frame>60 months</time_frame>
    <description>Time from the date of randomization in the current study to the start date of the second subsequent anticancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second progression or death (PFS2)</measure>
    <time_frame>60 months</time_frame>
    <description>Time from treatment randomization to the earliest date of assessment of progression on the next anticancer therapy following study treatment or death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Adverse Events</measure>
    <time_frame>60 months</time_frame>
    <description>Frequency and severity of adverse events as assessed by CTCAE version 4.03 for the regimens administered on this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported abdominal symptoms</measure>
    <time_frame>60 months</time_frame>
    <description>Clinically-meaningful improvement in patient-reported abdominal pain or bloating, defined as a 10-point decrease from the baseline score on either of the two items of the EORTC quality of life questionnaire-ovarian cancer module (QLQ-OV28) abdominal/GI symptom scale (items 31 and 32)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes (PROs) of function and health related quality of life (HRQoL)</measure>
    <time_frame>60 months</time_frame>
    <description>Clinical improvement, remaining stable, or deterioration in patient-reported function and HRQoL, defined as a 10-point increase, changes within 10 points, and a 10-point decrease, respectively, from the baseline score on each of the functional (physical, role, emotional, and social) and global health status/HRQoL scales of EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>60 months</time_frame>
    <description>Based on investigator assessment by RECIST v1.1 during the chemotherapy phase and during the maintenance phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>60 months</time_frame>
    <description>Based on investigator assessment by RECIST v1.1 during the chemotherapy phase and during the maintenance phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) from the beginning of the maintenance phase in all patients, in patients in complete or partial response after completing chemotherapy and in patients with stable disease after completing chemotherapy</measure>
    <time_frame>60 months</time_frame>
    <description>Period from start of maintenance treatment until disease progression, death or date of last contact assessed by the investigator according to RECIST v1.1 criteria, in all patients receiving maintenance treatment as well as in the subgroup of patients with complete response/partial response (CR/PR) of stable disease (SD) after completing chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) and BRCA status</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship of PFS with BRCA mutational status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) and BRCA status</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship of OS with BRCA mutational status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent therapy or death (TFST) and BRCA status</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship of TFST with BRCA mutational status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) and BRCA status</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship of ORR with BRCA mutational status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) and BRCA status</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship of DOR with BRCA mutational status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of atezolizumab</measure>
    <time_frame>60 months</time_frame>
    <description>Serum concentration (Cmax) of atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of atezolizumab</measure>
    <time_frame>60 months</time_frame>
    <description>Serum concentration (Cmin) of atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the incidence of anti-therapeutic antibody (ATAs)</measure>
    <time_frame>60 months</time_frame>
    <description>Incidence of ATAs during the study relative to the prevalence of ATAs at baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate PROs of disease associated with atezolizumab versus placebo</measure>
    <time_frame>60 months</time_frame>
    <description>Mean and mean changes from the baseline score in disease by cycle and between treatment arms as assessed by scale of european organization for research and treatment of cancer quality of life questionnaire core-30 (EORTC QLQ-C30)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate PROs of disease associated with atezolizumab versus placebo</measure>
    <time_frame>60 months</time_frame>
    <description>Mean and mean changes from the baseline score in disease by cycle and between treatment arms as assessed by scale quality of life questionnaire ovarian 28 (QLQ-OV28)</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate treatment-related symptoms associated with atezolizumab versus placebo</measure>
    <time_frame>60 months</time_frame>
    <description>Mean and mean changes from the baseline score in treatment-related symptoms by cycle and between treatment arms as assessed by all symptom item scale of EORTC QLQ-C30.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate treatment-related symptoms associated with atezolizumab versus placebo</measure>
    <time_frame>60 months</time_frame>
    <description>Mean and mean changes from the baseline score in treatment-related symptoms by cycle and between treatment arms as assessed by all symptom item scale of EORTC QLQ-OV28</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment burden</measure>
    <time_frame>60 months</time_frame>
    <description>Any treatment burden patients may experience in association with atezolizumab versus placebo, as measured by a single item (from GP5: &quot;I am bothered by side effects of treatment&quot;) from the physical wellbeing subscale of the Functional Assessment of Cancer Therapy - General (FACT-G) Quality of Life instrument</description>
  </other_outcome>
  <other_outcome>
    <measure>Patients' health utility</measure>
    <time_frame>60 months</time_frame>
    <description>Evaluate and compare between treatment arms patients' health utility as measured by European Quality of Life Visual Analogue Scale (EQ-VAS) to generate utility scores for use in economic models for reimbursement</description>
  </other_outcome>
  <other_outcome>
    <measure>Patients' health utility</measure>
    <time_frame>60 months</time_frame>
    <description>Evaluate and compare between treatment arms patients' health utility as measured by EuroQoL 5 Dimension to generate utility scores for use in economic models for reimbursement</description>
  </other_outcome>
  <other_outcome>
    <measure>Patients' health utility</measure>
    <time_frame>60 months</time_frame>
    <description>Evaluate and compare between treatment arms patients' health utility as measured by 5 Level Questionnaire (EQ-5D-5L) to generate utility scores for use in economic models for reimbursement</description>
  </other_outcome>
  <other_outcome>
    <measure>Association of PD-L1 expression and other immune biomarkers with clinical outcomes</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between tumour immune-related or disease type-related biomarkers (including but not limited to mutational burden, PD-L1, tumor-infiltrating lymphocytes (TILs) and cluster of differentiation (CD)8) in tumour tissues or blood samples, and clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers predictive of the response to atezolizumab.</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between exploratory biomarkers (circulating cell-free DNA) assessed from plasma before and during/after treatment, and clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers predictive of the response to atezolizumab.</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between exploratory biomarkers (proteins) assessed from plasma before and during/after treatment, and clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers predictive of the response to atezolizumab.</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between exploratory biomarkers (cytokines) assessed from plasma before and during/after treatment, and clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of antibiotic (ATB) use on the efficacy of atezolizumab.</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between ATB use within 2 month before and 1 month after the first study administration with atezolizumab efficacy as measured by PFS.</description>
  </other_outcome>
  <other_outcome>
    <measure>To evaluate the efficacy of atezolizumab vs placebo according to previous use of PARP inhibitors in front line.</measure>
    <time_frame>60 months</time_frame>
    <description>Relationship between previous use of PARP inhibitors in front line and clinical outcomes.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:
Carboplatin plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks
Carboplatin plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.
Carboplatin plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:
Carboplatin plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
Carboplatin plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.
Carboplatin plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <other_name>Placebo of Atezolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Intravenous. Day 1</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m². Intravenous. Day 1</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>200 mg or 300 mg. Oral. From day 1 to 21</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m². Intravenous. Day 1 and day 8.</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>30 mg/m². Intravenous. Day 1</description>
    <arm_group_label>Arm A (Control Arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg. Intravenous. Day 1</description>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years old

          2. Life expectancy ≥3 months

          3. Signed informed consent and ability to comply with treatment and follow-up

          4. Histologically confirmed diagnosis (cytology alone excluded) of high- grade serous or
             endometrioid ovarian, primary peritoneal or tubal carcinoma.

          5. BReast CAncer (BRCA) mutational status is known (germline or somatic)

          6. Relapsed disease more than 6 months after the last platinum dose

          7. No more than 2 prior lines of chemotherapy are allowed, and the last one must contain
             a platinum-based regimen

          8. At least one measurable lesion to assess response by RECIST v1.1 criteria.

          9. Archival tumor sample must be available. In the absence of an archival biopsy, a
             tumour tissue biopsy will need to be collected prior to study enrolment.

         10. Performance status determined by Eastern Cooperative Oncology Group (ECOG) score of
             0-1

         11. Normal organ and bone marrow function:

               -  Haemoglobin ≥10.0 g/dL

               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L

               -  Lymphocyte count ≥0.5 × 109/L

               -  Platelet count ≥100 x 109/L

               -  Total bilirubin ≤1.5 x institutional upper limit of normal (ULN)

               -  Serum albumin ≥2.5 g/dL

               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 x ULN,
                  unless liver metastases are present in which case they must be ≤5 x ULN

               -  Serum creatinine ≤1.5 x institutional ULN or calculated creatinine clearance ≥ 30
                  mL/min using the Cockcroft-Gault equation

               -  Patients not receiving anticoagulant medication must have an International
                  Normalized Ratio (INR) ≤1.5 and an Activated ProThrombin Time (aPTT) ≤1.5 x ULN.

         12. Negative Test Results for Hepatitis.

         13. Toxicities related to previous treatments must be recovered to &lt; grade 2

         14. Female participants must be postmenopausal or surgically sterile or otherwise have a
             negative serum pregnancy test within 7 days of the first study treatment and agree to
             abstain from heterosexual intercourse or use single or combined contraceptive methods.

         15. Participant must agree to not donate blood during the study or for 90 days after the
             last dose of study treatment.

         16. Participant must agree to not breastfeed during the study or for 180 days after the
             last dose of study treatment.

        Exclusion Criteria:

          1. Non-epithelial tumor of the ovary, the fallopian tube or the peritoneum.

          2. Ovarian tumors of low malignant potential or low grade

          3. Other malignancy within the last 5 years except curatively treated non-melanoma skin
             cancer, in situ cancer of the cervix and ductal carcinoma in situ (DCIS)

          4. Major surgery within 4 weeks of starting study treatment or patients who have not
             completely recovered (Grade ≥ 2) from the effects of any major surgery at
             randomization

          5. Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1, Cycle 1

          6. Administration of other chemotherapy drugs, anticancer therapy or anti-neoplastic
             hormonal therapy, or treatment with other investigational agents or devices within 28
             days prior to randomization, or within a time interval less than at least 5 half-lives
             of the investigational agent, whichever is shorter, or anticipation to do it during
             the trial treatment period (non-investigational hormonal replacement therapy is
             permitted)

          7. Palliative radiotherapy (e.g., for pain or bleeding) within 6 weeks prior to
             randomization or patients who have not completely recovered (Grade ≥ 2) from the
             effects of previous radiotherapy

          8. Current or recent (within 10 days prior to randomization) chronic use of aspirin (&gt;325
             mg/day) or clopidogrel (&gt;75 mg/day)

          9. Clinically significant (e.g. active) cardiovascular disease

         10. Resting ECG with corrected QT interval (QTc) &gt;470 msec on 2 or more time points within
             a 24 hour period or family history of long QT syndrome

         11. Left ventricular ejection fraction defined by multigated acquisition/echocardiogram
             (MUGA/ECHO) below the institutional lower limit of normal (only applicable for
             patients intended to be treated with pegylated liposomal doxorubicin)

         12. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI
             of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected
             brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in
             case of suspected spinal cord compression

         13. History or evidence upon neurological examination of central nervous system (CNS)
             disorders (e.g. uncontrolled epileptic seizures) unless adequately treated with
             standard medical therapy

         14. Current, clinically relevant bowel obstruction, including sub-occlusive disease,
             related to underlying disease

         15. Uncontrolled tumor-related pain

         16. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently). Patients with indwelling
             catheters (e.g., PleurX) are allowed

         17. Uncontrolled hypercalcemia (&gt;1.5 mmol/L ionized calcium or calcium &gt;12 mg/dL or
             corrected serum calcium &gt; ULN) or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab

         18. Evidence of any other disease, metabolic dysfunction, physical examination finding or
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or puts the patient at high risk
             for treatment related complications

         19. Pregnant or lactating women

         20. Simultaneously receiving therapy in any interventional clinical trial

         21. Prior treatment with CD137 agonists or immune checkpoint stimulating or blockade
             therapies, such as anti−PD1, anti−PDL1 or anti-CTLA4 therapeutic antibodies

         22. Treatment with systemic immunostimulatory agents (including but not limited to
             interferon-alpha (IFN-α) and interleukin-2 (IL-2) within 4 weeks or five half-lives of
             the drug (whichever is shorter) prior to Cycle 1, Day 1

         23. Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,
             azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor (TNF) agents)
             within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic
             immunosuppressive medications during the trial

         24. History of autoimmune disease, including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis

         25. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
             organizing pneumonia), or evidence of active pneumonitis

         26. Immunocompromised patients, e.g., patients who are known to be serologically positive
             for human immunodeficiency virus (HIV)

         27. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1

         28. Active tuberculosis

         29. Administration of a live, attenuated vaccine (including against influenza) within 4
             weeks prior to Cycle 1, Day 1 or anticipation that it will be administered at any time
             during the treatment period of the study

         30. History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

         31. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
             ovary cells or to any component of the atezolizumab formulation or allergy to any of
             the other drugs included in the protocol or their solvents (including to Cremophor®)

         32. Patient has received prior treatment with a poly (adenosine diphosphate (ADP)-ribose)
             polymerase (PARP) inhibitor in the recurrent setting or has participated in a study
             where any treatment arm included administration of a PARP inhibitor in the recurrent
             setting, unless the patient is unblinded and there is evidence of not having received
             a PARP inhibitor

         33. Patient has had any known ≥Grade 3 hematological toxicity anemia, neutropenia or
             thrombocytopenia due to prior cancer chemotherapy that persisted &gt;4 weeks and was
             related to the most recent treatment

         34. Patient has any known history or current diagnosis of Myelodysplasic syndrome (MDS) or
             Anaplastic Myeloid Leukemia (AML)

         35. Previous allogeneic bone marrow transplant or previous solid organ transplantation

         36. Patient has a condition (such as transfusion dependent anemia or thrombocytopenia),
             therapy, or laboratory abnormality that might confound the study results or interfere
             with the patient's participation for the full duration of the study treatment

         37. Participant has any known hypersensitivity to niraparib components or excipients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Gonzalez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universitaria de Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Sanchez, MBA MSc</last_name>
    <phone>+34 669 528 261</phone>
    <email>jsanchez@grupogeico.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Marqués, MD</last_name>
    <email>cmarques@grupogeico.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU St. Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corina Martinez-mena, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corina Martinez-mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL St. Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu Luyckx, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu Luyckx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Honhon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte Honhon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Vulsteke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christof Vulsteke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toon Van Gorp, MD</last_name>
    </contact>
    <investigator>
      <last_name>Toon Van Gorp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, site Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric Kridelka, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric Kridelka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Cornez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie Cornez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur site St. Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Henry, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hochtaunus-Kliniken</name>
      <address>
        <city>Bad Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominik Denschlag, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominik Denschlag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin (CVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Ioana Braicu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Ioana Braicu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Heitz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florian Heitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beate Rautenberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beate Rautenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antje Belau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antje Belau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mammazentrum Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Hilpert, MD</last_name>
    </contact>
    <investigator>
      <last_name>Felix Hilpert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakovere Krankenhaus</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Lübbe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kristina Lübbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Olaf Bauerschlag, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dirk Olaf Bauerschlag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Kulmbach</name>
      <address>
        <city>Kulmbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benno Lex, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benno Lex, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Holtschmidt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Johannes Holtschmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Cirkel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Cirkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Witteler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ralf Witteler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MVZ Nordhausen</name>
      <address>
        <city>Nordhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Grafe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Grafe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg AöR</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus-Henning Koehne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claus-Henning Koehne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Schnelzer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Schnelzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Kommoss, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Kommoss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolaus de Gregorio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nikolaus de Gregorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Dr. Horst Schmidt Kliniken Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Eichbaum, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Eichbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Germana Tognon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Germana Tognon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asst Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Ardizzoia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Ardizzoia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoletta Colombo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicoletta Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MariaOrnella Nicoletto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Ornella Nicoletto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Bologna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Bologna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Città della Salute e della Scienza- Ospedale Sant'Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Zola, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Zola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annamaria Ferrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annamaria Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yolanda García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Quindós, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Quindós, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Romeo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Romeo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Gaba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lydia Gaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Martin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Belén Ojeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Oaknin, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Oaknin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Reina Sofía Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jesus Rubio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jesus Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Barretina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pilar Barretina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Hospitalet del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Pardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Miguel de Sande, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Miguel de Sande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gonzalez, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio González, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Marquina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gloria Marquina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Pérez Ramírez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sara Pérez Ramírez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Manso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Manso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Casado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Casado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Guerra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eva Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garcia Martinez, Md</last_name>
    </contact>
    <investigator>
      <last_name>Elena García Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose´ Bermejo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria José Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Iglesias González, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Iglesias González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Purificación Estévez García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Purificación Estévez García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Santaballa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Santaballa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José A Pérez Fidalgo, MD</last_name>
    </contact>
    <investigator>
      <last_name>José A Pérez Fidalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Eugenia Ortega, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mª Eugenia Eugenia Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Niraparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Niraparib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

